Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 13/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566315 | 0.82 | S1PR1 (0.39) | AHRS1PR1F2RL3ALDH1A1RECQL | |
| SCHEMBL10139327 | 0.71 | AHR (0.46) | AHRF2RL3ALDH1A1MCL1 | |
| SCHEMBL566657 | 0.71 | AHR (0.43) | AHR | |
| SCHEMBL21355070 | 0.68 | CA12 (0.44) | AHR | |
| SCHEMBL16345372 | 0.65 | AHR (0.34) | AHR | |
| SCHEMBL17193877 | 0.65 | NPC1 (0.36) | AHRF2RL3HPGD | |
| SCHEMBL16345100 | 0.65 | MCL1 (0.51) | AHRMCL1 | |
| SCHEMBL9663355 | 0.65 | AHR (0.35) | AHR | |
| SCHEMBL16708179 | 0.65 | MCL1 (0.50) | AHRF2RL3ALDH1A1KDM4EHPGD | |
| SCHEMBL18325887 | 0.64 | MCL1 (0.50) | AHRALDH1A1KDM4ECASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | AHR 1625/4885S1PR1 1/4885F2RL3 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.